Atara Biotherapeutics - ATRA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $19.50
  • Forecasted Upside: 277.18%
  • Number of Analysts: 7
  • Breakdown:
  • 2 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$5.17
▼ -0.29 (-5.31%)

This chart shows the closing price for ATRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Atara Biotherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATRA

Analyst Price Target is $19.50
▲ +277.18% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Atara Biotherapeutics in the last 3 months. The average price target is $19.50, with a high forecast of $50.00 and a low forecast of $3.00. The average price target represents a 277.18% upside from the last price of $5.17.

This chart shows the closing price for ATRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 7 investment analysts is to hold stock in Atara Biotherapeutics. This rating has held steady since April 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
8/15/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
11/13/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
2/11/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
5/12/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 2 sell ratings
8/10/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 2 sell ratings
11/8/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 2 sell ratings
1/7/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 2 sell ratings
2/6/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$25.00Low
8/16/2022MizuhoLower TargetBuy$39.00 ➝ $31.00Low
8/9/2022The Goldman Sachs GroupLower TargetSell$4.00 ➝ $3.00Low
7/20/2022CitigroupDowngradeNeutral ➝ Sell$8.00 ➝ $3.00Low
7/13/2022Canaccord Genuity GroupLower Target$67.00 ➝ $50.00Low
7/13/2022Stifel NicolausDowngradeBuy ➝ Hold$16.00 ➝ $5.00N/A
7/13/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$10.00N/A
5/24/2022The Goldman Sachs GroupLower TargetSell$5.00 ➝ $4.00Low
5/23/2022HC WainwrightLower TargetBuy$31.00 ➝ $29.00High
5/9/2022CitigroupDowngradeBuy ➝ Neutral$15.00 ➝ $8.00High
3/28/2022JPMorgan Chase & Co.Lower TargetOverweight$27.00 ➝ $22.00Low
3/1/2022Canaccord Genuity GroupLower Target$78.00 ➝ $67.00High
1/27/2022HC WainwrightReiterated RatingBuy$31.00High
1/14/2022HC WainwrightReiterated RatingBuy$31.00High
1/3/2022JPMorgan Chase & Co.Boost TargetOverweight$26.00 ➝ $27.00High
10/13/2021MizuhoInitiated CoverageBuy$41.00High
10/5/2021HC WainwrightReiterated RatingBuy$31.00Low
10/4/2021Stifel NicolausLower TargetBuy$30.00 ➝ $27.00Low
9/29/2021MizuhoInitiated CoverageBuy$41.00High
9/28/2021HC WainwrightReiterated RatingBuy$31.00High
5/13/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$23.00 ➝ $29.00Low
5/5/2021HC WainwrightLower TargetBuy$32.00 ➝ $31.00High
3/2/2021William BlairReiterated RatingOutperformLow
3/2/2021CitigroupUpgradeNeutral ➝ Buy$27.00High
12/9/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral$20.00 ➝ $27.00High
12/8/2020HC WainwrightReiterated RatingBuy$28.00 ➝ $31.00Medium
12/7/2020Stifel NicolausBoost TargetBuy$28.00 ➝ $33.00Medium
11/23/2020MizuhoBoost TargetBuy$38.00 ➝ $41.00Low
11/13/2020Smith Barney CitigroupBoost Target$14.00 ➝ $20.00Low
11/10/2020HC WainwrightBoost TargetBuy$26.00 ➝ $28.00High
9/24/2020William BlairReiterated RatingBuyHigh
8/6/2020Stifel NicolausLower TargetBuy$30.00 ➝ $28.00Low
8/6/2020HC WainwrightBoost TargetBuy$25.00 ➝ $26.00High
6/30/2020Evercore ISIInitiated CoverageOutperformMedium
6/15/2020HC WainwrightInitiated CoverageBuy$25.00High
5/26/2020MizuhoInitiated CoverageBuy$38.00High
5/19/2020MizuhoInitiated CoverageBuy$38.00High
5/12/2020JPMorgan Chase & Co.Boost TargetNeutral$22.00 ➝ $23.00High
4/23/2020CitigroupUpgradeNeutral ➝ Buy$14.00High
12/10/2019CowenReiterated RatingBuyMedium
11/8/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$43.00 ➝ $22.00Low
10/25/2019Stifel NicolausReiterated RatingBuyLow
9/27/2019The Goldman Sachs GroupDowngradeNeutral ➝ Sell$14.00 ➝ $9.00Medium
9/18/2019MizuhoSet TargetBuy$43.00Low
9/16/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$32.00 ➝ $15.00Medium
9/13/2019Stifel NicolausSet TargetBuy$36.00Low
9/13/2019CowenReiterated RatingBuyHigh
9/13/2019Roth CapitalInitiated CoverageBuy$30.00High
9/11/2019MizuhoSet TargetBuy$43.00Medium
8/12/2019CitigroupSet TargetHold$14.00High
7/16/2019CowenReiterated RatingBuyHigh
6/3/2019CitigroupUpgradeSell ➝ Neutral$23.00 ➝ $24.00High
5/30/2019Roth CapitalInitiated CoverageBuy$30.00Medium
5/29/2019WedbushReiterated RatingOutperformHigh
5/22/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$41.00Low
5/16/2019William BlairReiterated RatingBuyLow
5/9/2019MizuhoReiterated RatingBuy$62.00High
4/21/2019MizuhoReiterated RatingBuy$62.00Low
4/1/2019William BlairReiterated RatingOutperformLow
2/26/2019CowenReiterated RatingBuyHigh
2/26/2019MizuhoReiterated RatingBuy$62.00High
1/22/2019MizuhoInitiated CoverageBuy ➝ Buy$62.00Low
11/30/2018CowenReiterated RatingBuyHigh
8/3/2018Jefferies Financial GroupReiterated RatingBuy$45.00Low
6/11/2018CitigroupLower TargetSell ➝ Sell$25.00 ➝ $23.00Medium
4/10/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$56.00High
4/6/2018William BlairReiterated RatingBuyMedium
3/20/2018William BlairReiterated RatingOutperformHigh
3/15/2018GuggenheimInitiated CoverageNeutral ➝ NeutralLow
3/5/2018Jefferies Financial GroupBoost TargetBuy ➝ Buy$30.00 ➝ $46.00High
2/28/2018JMP SecuritiesDowngradeOutperform ➝ Market PerformHigh
2/15/2018CitigroupDowngradeNeutral ➝ SellHigh
(Data available from 2/6/2018 forward)

News Sentiment Rating

0.48 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/11/2022
  • 3 very positive mentions
  • 11 positive mentions
  • 5 negative mentions
  • 3 very negative mentions
8/10/2022
  • 5 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
9/9/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/9/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
11/8/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
12/8/2022
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
1/7/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/6/2023

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Atara Biotherapeutics logo
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.
Read More

Today's Range

Now: $5.17
Low: $5.16
High: $5.38

50 Day Range

MA: $4.00
Low: $2.85
High: $5.46

52 Week Range

Now: $5.17
Low: $2.83
High: $16.07

Volume

783,000 shs

Average Volume

1,064,400 shs

Market Capitalization

$490.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94

Frequently Asked Questions

What sell-side analysts currently cover shares of Atara Biotherapeutics?

The following equities research analysts have issued reports on Atara Biotherapeutics in the last twelve months: Canaccord Genuity Group Inc., Citigroup Inc., EF Hutton Acquisition Co. I, HC Wainwright, JPMorgan Chase & Co., Mizuho, Stifel Nicolaus, StockNews.com, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for ATRA.

What is the current price target for Atara Biotherapeutics?

8 Wall Street analysts have set twelve-month price targets for Atara Biotherapeutics in the last year. Their average twelve-month price target is $19.50, suggesting a possible upside of 277.2%. Canaccord Genuity Group Inc. has the highest price target set, predicting ATRA will reach $50.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $3.00 for Atara Biotherapeutics in the next year.
View the latest price targets for ATRA.

What is the current consensus analyst rating for Atara Biotherapeutics?

Atara Biotherapeutics currently has 2 sell ratings, 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ATRA, but not buy more shares or sell existing shares.
View the latest ratings for ATRA.

What other companies compete with Atara Biotherapeutics?

How do I contact Atara Biotherapeutics' investor relations team?

Atara Biotherapeutics' physical mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company's listed phone number is (650) 278-8930 and its investor relations email address is [email protected] The official website for Atara Biotherapeutics is www.atarabio.com. Learn More about contacing Atara Biotherapeutics investor relations.